PMID- 38349218
OWN - NLM
STAT- Publisher
LR  - 20240213
IS  - 1743-9159 (Electronic)
IS  - 1743-9159 (Linking)
DP  - 2024 Feb 13
TI  - Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with 
      different risk factors for stage II-III colon cancer: a meta-analysis.
LID - 10.1097/JS9.0000000000001175 [doi]
AB  - BACKGROUND: The duration of oxaliplatin-based chemotherapy in high-risk stage II, 
      low-risk stage III, and high-risk stage III colon cancer patients is 
      controversial. To reduce the risk of adverse events (AEs) without compromising 
      efficacy while improving chemotherapy compliance is crucial. METHODS: We searched 
      Cochrane, Embase, Pubmed, and Web of Science databases for articles from 
      inception to 2023.8.8, the main outcomes were disease-free survival, overall 
      survival, chemotherapy completion rates, and AE frequency. RESULTS: Six 
      randomized controlled trials involving 10,332 patients were included. 
      Disease-free survival analysis revealed that only the high-risk stage III colon 
      cancer patients experienced better results with the six-month FOLFOX regimen when 
      compared with the 3-month regimen (Hazard ratio [HR]: 1.32, 95% CI: 1.15-1.51, 
      P<0.0001). Overall survival analysis revealed that extending the use of FOLFOX 
      and CAPEOX regimens did not provide survival benefits for stage III colon cancer 
      patients (HR: 1.16, 95% CI: 0.9-1.49, and HR: 0.89, 95% CI: 0.67-1.18, P=0.40). 
      The completion rate of the three-month oxaliplatin-based adjuvant chemotherapy 
      regimen was significantly higher than that of the six-month regimen (Relative 
      risk [RR]: 1.16, 95% CI: 1.06-1.27, P=0.002). Moreover, the three-month regimen 
      had significantly lower AE rates than the six-month regimen (RR: 0.62, 95% CI: 
      0.57-0.68, P<0.00001), with differences mainly concentrated in grade 3/4 
      neutropenia (RR: 0.70, 95% CI: 0.59-0.85, P=0.0002), peripheral sensory 
      neuropathy at>/=grade 2 (RR: 0.45, 95% CI: 0.38-0.53, P<0.00001), and hand-foot 
      syndrome at>/=grade 2 (RR: 0.36, 95% CI: 0.17-0.77, P=0.009). CONCLUSIONS: The 
      six-month FOLFOX regimen should only be recommended for high-risk stage III colon 
      cancer, while the three-month regimen can be recommended for other stages. A 
      three-month CAPEOX regimen can be recommended for stage II-III colon cancer.
CI  - Copyright (c) 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Kuang, Ziyu
AU  - Kuang Z
AD  - Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 
      100053, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Wang, Jiaxi
AU  - Wang J
AD  - Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 
      100053, China.
FAU - Liu, Kexin
AU  - Liu K
AD  - Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 
      100053, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Wu, Jingyuan
AU  - Wu J
AD  - Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 
      100053, China.
AD  - Beijing University of Chinese Medicine, Beijing 100029, China.
FAU - Li, Jie
AU  - Li J
AD  - Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 
      100053, China.
LA  - eng
PT  - Journal Article
DEP - 20240213
PL  - United States
TA  - Int J Surg
JT  - International journal of surgery (London, England)
JID - 101228232
SB  - IM
EDAT- 2024/02/13 12:46
MHDA- 2024/02/13 12:46
CRDT- 2024/02/13 09:33
PHST- 2023/12/19 00:00 [received]
PHST- 2024/01/29 00:00 [accepted]
PHST- 2024/02/13 12:46 [medline]
PHST- 2024/02/13 12:46 [pubmed]
PHST- 2024/02/13 09:33 [entrez]
AID - 01279778-990000000-01074 [pii]
AID - 10.1097/JS9.0000000000001175 [doi]
PST - aheadofprint
SO  - Int J Surg. 2024 Feb 13. doi: 10.1097/JS9.0000000000001175.